Paediatric Diseases Working Party (PDWP)
Type d'étude:
Numéro de l'étude:
8417027
Type de traitement à base de cellules souches:
Allogeneic - Haploidentical
Maladies:
Acute Lymphatic Leukaemia (ALL)
Acute Myeloid Leukaemia (AML)
Titre court:
PT-Cy based haploidentical HSCT for Acute Leukemia
Objectif principal:
Primary end point:
Leukemia-free survival (LFS)
Secondary end points are:
Haematopoietic recovery, grades II-IV and grade III-IV GVHD, chronic GVHD, transplantation-related mortality, relapse, GRFS and OS
Leukemia-free survival (LFS)
Secondary end points are:
Haematopoietic recovery, grades II-IV and grade III-IV GVHD, chronic GVHD, transplantation-related mortality, relapse, GRFS and OS
Principaux critères d'inclusion:
1) Patient age less/= than 18 years
2) Patient diagnosed with either ALL or AML
3) Patient who underwent a first allograft between 2010 and 2016 included.
4) Patient which received unmanipulated (non TCD) haploidentical stem cell transplantation
5) Post-transplant cyclophosphamide as GVHD prophylaxis
2) Patient diagnosed with either ALL or AML
3) Patient who underwent a first allograft between 2010 and 2016 included.
4) Patient which received unmanipulated (non TCD) haploidentical stem cell transplantation
5) Post-transplant cyclophosphamide as GVHD prophylaxis
Pays:
Italie
Investigateur principal:
Annalisa Ruggeri
Coordinateur EBMT de l'étude:
Arnaud Dalissier
E-mail du coordinateur de l'étude:
arnaud.dalissier@upmc.fr